retatrutide dosage trials Retatrutide—A Game Changer in Obesity Pharmacotherapy retatrutide clinical trial dosing frequency

As we move through 2026, patients should: Stay informed about regulatory developments affecting compounded GLP-1 access Monitor their own experiences carefully and report any serious side effects Maintain open communication with both telehealth providers and primary care doctors Recognize that sustainable weight management involves multiple factors beyond medication alone Plan for financial sustainability of long-term treatment For people who've struggled with obesity and its associated health risks, GLP-1 medications represent an important advancement in medical weight management

Large-scale CVOTs have demonstrated that GLP-1 RAs significantly reduce the incidence of MACE, including cardiovascular death, non-fatal MI and non-fatal stroke

A GLP-1 drug shortage has persisted since late 2022

Medications like Wegovy, Ozempic, and others are covered under TRICARE, but not in the way most families expect

Phase 3 (ongoing): the TRIUMPH program is the pivotal Phase 3 effort